Bernstein SocGen Group analyst Courtney Breen raised the price target on Merck (NYSE: MRK) to $105.00 (from $100.00) while maintaining a Market Perform rating.

The analyst commented: "We update our PT to $105 for the quarter to better reflect the diversifying business & underlying performance (equally balanced across DCF & P/E multiple valuation approaches- with an 11.5x multiple implied on ‘27), however we continue to do more diligence to evaluate how much more pipeline value can be attributed with current data in hand. On the quarter, we expect MRK to meet consensus expectations on revenue, with a risk of slight miss on EPS (we forecast $16.326B v $16.365B and EPS of $0.24 vs cons of $0.26). We expect questions on Tulisokibart readout, plans for the enlicitide launch & investors continuing to wonder if Merck is finished with M&A."